Overview / Abstract: |
Alzheimer disease (AD) is associated with a significant and increasing burden for patients, their caregivers, and society as the population ages. This activity has been designed with differing educational pathways for specialists and nonspecialists to address the needs of their clinical practices, and will help clinicians identify and differentiate AD from normal aging and other neurocognitive disorders through optimal use of cognitive, imaging, and biomarker assessments to enable the earlier diagnosis of AD and allow for earlier intervention to improve patient outcomes. |
Expiration |
Jun 28, 2023 |
Format |
Online |
Credits / Hours |
1.0 |
Accreditation |
ACCME |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
Andrew E. Budson, MD |
Sponsors / Supporters / Grant Providers |
Sponsored by Penn State College of Medicine and the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Biogen. |
Keywords / Search Terms |
ACHL Continuing Medical Education, CME/CE,Online Learning, Case Study, Alzheimer’s, Alzheimer’s disease, Alzheimer, Alzheimer disease, Andrew E. Budson, MD, biomarker testing, cerebrospinal fluid (CSF), fluorodeoxyglucose (FDG), neurodegeneration, brief cognitive test, imaging, MRI, CT, cognitive testing, amyloid, tau, PET, Mini-Cog, mild cognitive impairment, MCI, Mini-Mental State Examination, MMSE, Montreal Cognitive Assessment Free CE CME Live CE CME |